Addex Pharmaceuticals enters into Collaboration with Ortho-McNeil Pharmaceutical to Develop Novel Treatments

18-Jan-2005

Addex Pharmaceuticals announced that it has entered an exclusive worldwide research collaboration and licence agreement with Ortho-McNeil Pharmaceutical, Inc. to discover, develop and commercialize novel compounds modulating allosterically G-Protein Coupled Receptors for the treatment of anxiety, depression, schizophrenia and Alzheimer's disease. The initial drug discovery research will be conducted both at Addex and at Johnson & Johnson Pharmaceutical Research and Development (''J&JPRD''), a division of Janssen Pharmaceutica NV.

Through a joint steering committee, Addex and J&JPRD will collaborate in all phases of research and development up to clinical proof of concept. Addex' expertise in allosteric modulator pharmacology will be combined with the recognised expertise of J&JPRD in the fields of psychiatry and neurology. Allosteric modulators are expected to have greater selectivity, which may give them a significant competitive advantage in the treatment of anxiety, depression, schizophrenia and Alzheimer's disease.

Under the terms of the agreement, Ortho-McNeil will pay Addex an upfront fee and research funding for 2 years. In addition, Addex will be eligible for payments on successful achievement of pre-specified scientific, clinical and regulatory milestones, and royalties on product sales.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...

Last viewed contents

Cerenis Therapeutics raises additional €10 million to close €50 million Series C financing

Genetic mutations that lead to macular degeneration blindness mapped by new research

Genetic mutations that lead to macular degeneration blindness mapped by new research

Barroso Commission recognises contribution of biotech crops to European competitiveness

BioVaria Start-up Awards go to ISD Immunotech and Mindpax.me

Alnylam Announces Manufacturing Agreement with Dowpharma(TM) for RNAi Therapeutics

Atugen AG raises EUR 5 million venture funding for siRNA therapeutics program - siRNA therapeutics patent application published

Vantia Therapeutics’ lead candidate VA106483 enters Phase IIb trial for nocturia

Organon and Schering to continue research in male fertility control separately

A human enzyme (CD 39) targets the Achilles heel of sepsis - New research suggests that CD39 significantly improves survival of mice in severe sepsis

Borean Pharma Acquires Proteopharma and Promising Arterial Drug

Vernalis extends cancer research collaboration with Novartis Institutes for BioMedical Research - Joint research and development programme on Hsp90, a target implicated in a number of different cancers - Vernalis to receive a $1.5 million signature fee - Novartis to make an investment in new Vernalis shares of approximately ?5 million

Horizon Discovery Group plc, Centre for Process Innovation and University of Manchester Awarded £1.67M - Consortium to receive funding to develop enhanced biomanufacturing platforms based on the Company’s CHO cell line and gene editing platform